Atopic skin diathesis rather than atopic dermatitis is associated with specific contact allergies

Supporting information for this article is available on the WWW under https://doi.org/10.1111/ddg.14341

Summary

Background: The association of atopic dermatitis (AD) and allergic contact dermatitis has been a matter of considerable uncertainty. Study results range from lack of any association to increased sensitization for multiple allergens, but fail to identify consistent allergen associations.

Objective: We studied a large patch test cohort of patients stratified by their atopic skin diathesis using the Erlangen Atopy Score (EAS), independent of active skin disease.

Methods: Retrospective multi-center data analysis from five departments of dermatology in Germany with 4,509 patients. Patients were grouped as “no atopic skin diathesis” (n = 2,165) and “atopic skin diathesis” (n = 1,743), according to EAS.

Results: Significantly more individuals with atopic skin diathesis showed at least one positive patch test reaction to the baseline series compared to individuals without atopic skin diathesis (49.1 % vs. 38.3 %). In logistic regression analyses, atopic skin diathesis was associated with a significantly higher risk of sensitization to methylchloroisothiazolinone/methylisothiazolinone (OR 2.383) and methylisothiazolinone (OR 1.891), thiuram mix (OR 1.614), as well as nickel (OR 1.530), cobalt (OR 1.683), and chromium (OR 2.089).

Conclusions: Atopic skin diathesis proved to be the most important intrinsic risk factor for contact sensitization to few, specific allergens. Past or present AD was a less relevant variable.
Introduction

Atopic Dermatitis (AD) is a common chronic inflammatory skin disease, which severely affects the quality of the patient’s life. It affects up to 10–20% of the population in industrialized countries [1, 2]. The multifactorial pathogenesis of AD comprises complex immune dysregulation and epidermal barrier defects. In contrast, allergic contact dermatitis (ACD) requires the penetration of the epidermal barrier by an allergen or hapten. After recognition by antigen-presenting cells, the cascade of sensitization and elicitation follows a predominantly Th1-cell mediated immune response with additional roles for Th2, Th17, and Th22 cells [3]. In line with these considerations, there is a strong association of ACD with occupational dermatitis [4]. Interestingly, recent studies revealed distinct activation and polarization modalities of T cells depending on the allergen in question. Nickel exposure induced a Th1-polarization and Th17/Th22 cell activation, whereas immune responses to fragrance and rubber was mainly driven by the Th2/Th22 axis [5, 6]. Since AD patients treat their skin with emollients and medical ointments daily, this repeated exposure to potential allergens was alleged to be accountable for the frequent sensitizations in these individuals. However, the causal link between AD and ACD is still the subject of controversial discussions, as the existing data are far from clear.

A Danish study revealed no significant differences in the frequency of positive patch test results in AD patients compared to healthy controls [7]. However, the diagnosis AD was based on “past or present AD diagnosis” according to UK-criteria [8], which was partly evaluated by nurses. After adjustment for age, the authors found in patients with AD significantly more sensitizations to potassium dichromate and significantly fewer positive reactions to nickel. Another Danish study investigated 3,202 participants from the general population by patch tests and filaggrin-genotyping [9]. Again, the diagnosis of AD was based on the UK-criteria [8]. At least one positive patch test reaction was found in 13.6% of individuals with reported AD vs. a significantly lower rate of 9.5% in people without AD. The higher sensitization rate was mainly due to fragrances. In a large multicenter study from Germany, individuals were grouped into patients with or without physician-diagnosed AD (n = 9,020 and n = 15,263, respectively) [10]. Here, the diagnosis of AD was based on criteria by Hanifin and Rajka [11]. The frequency of positive patch test results to one or more allergens was equally distributed between both groups [10]. Interestingly, significantly elevated sensitization rates in AD patients were found for fragrance mix, composite mix, thiram mix, MCI/MI, and bufexamac.

Several studies investigated the presence of ACD in patients with AD, with controversial results [10, 12, 13]. Given that recent studies have shown an immunological and barrier-compromising pre-activation of cells and cytokines even in unaffected skin of patients with atopic dermatitis [14, 15], we chose a different, more refined approach: Atopic skin diathesis can be thoroughly assessed by the Erlangen Atopy Score (EAS) which was established and validated in the 1990s by Thomas Diepgen and colleagues [16, 17]. This at least in Germany well-established and widely used score integrates 24 items to measure and calculate the probability of atopic skin diathesis (Table S1, online Supporting Information). The criteria comprise personal and family history, subjective symptoms such as itch when sweating, clinical signs, and laboratory results.

The different prevalences of ACD in AD in previous studies may be due to inconsistent AD diagnosis criteria. Unfortunately, no single parameter can unequivocally establish the diagnosis of AD. In a recently published review on “diagnostic criteria used in AD randomized controlled trials”, 212 randomized controlled AD trials with pharmacological intervention were analyzed [18]. In 37% of the trials, “no validated criteria specified” were used for AD diagnosis. In the remaining trials with specified diagnostic criteria, the “Hanifin and Rajka” criteria were used in two thirds of these [11]. This diagnostic score contains 28 items (4 major criteria and 24 minor criteria) and is frequently used for diagnosis of AD. Importantly, three distinct features separate EAS from the “Hanifin and Rajka” criteria: First, the EAS encourages evaluation of the items with partial points (minimum 0.5 to maximum of 3 points) which consequently allows better distinction. Second, the EAS includes more laboratory parameters (total and specific IgE). Third, the EAS assesses probability of atopic skin diathesis without necessity of present or past eczema manifestation. Previous studies reported conflicting data regarding the association of AD with contact dermatitis. To the best of our knowledge, no data have yet been published on correlation of atopic skin diathesis with contact allergy. Thus, we stratified our study cohort of 4,509 patients into two groups with and without atopic skin diathesis.

Patients and Methods

This retrospective, multi-center study is based on clinical data collected by the Information Network of Departments of Dermatology (IVDK) during the years 2008–2014. Structure and operating procedures of the IVDK have been described elsewhere [19]. The EAS is a voluntary part of the IVDK patient data documentation. We selected data from five German centers in which the EAS was recorded routinely in all patch tested patients: BG Clinic Falkenstein, SLK Clinics Heilbronn as well as University Hospitals Erlangen, Heidelberg and Marburg. Clinical data and patch test results of all patients were documented electronically in a standardized manner.
and transmitted to the IVDK central office at the University of Göttingen. Patch testing with the baseline series of the German Contact Dermatitis Research Group (DKG) was performed according to DKG guidelines [20]. From 2008–2013, tests were performed with commercial test preparations from Almirall Hermal, Reinbek, Germany. In 2014, patch test preparations were obtained from Smart Practice Europe, Reinbek, Germany. Compositae mix II was purchased from Chemotechnique, Vellinge, Sweden. ECT preparations were dispensed into Finn chambers® (8 mm inner diameter) and fixed on Scanpor tape® (Smart Practice). The patches were applied to the upper back and left for 48 h. Patches were read on days 2 (48 h), 3 (72 h), and 4 (96 h). A positive response was graded as a +, ++ or +++ reaction, corresponding to infiltration, papules and/or vesicles, respectively [21]. Erythema only (without palpable infiltrate), irritant or follicular reactions in the test fields were not considered as positive.

According to IVDK guidelines, AD was diagnosed by a dermatologist if a manifest eczema was present or had been present in the past. Minimal variants of AD such as the exclusive presence of Dennie-Morgan infraorbital fold, infraauricular fissure, or periocular pigmentation were excluded. Allergic rhinitis was diagnosed if current/intermittent and/or persistent allergic rhinitis and/or conjunctivitis were present. Similar criteria applied to bronchial asthma. Aspirin-induced asthma, stress-induced asthma without allergic compound, and all other forms of non-allergic obstructive airway diseases were excluded. Individual atopic skin diathesis independent of active skin disease was assessed by the EAS (Table S1a, online Supporting Information) [16, 17]. The atopy score and its likelihood of atopic skin diathesis and percentages of present AD are depicted in Table S1b (online Supporting Information). An EAS ≥ 7 is rated with “no and/or improbable risk” of atopic skin diathesis. An EAS ≥ 10 was considered as atopic skin predisposition/diathesis [16]. A total of 4,509 patients were available for data analysis. Since scoring 8–9 points in EAS is considered to be unreliable for predicting atopic skin diathesis, all patients with a final EAS of 8–9 points were excluded from subgroup analyses. Thus, the final study cohort for subgroup analysis comprised of 3,908 patients scoring ≤ 7 or ≥ 10, respectively.

Additionally, clinical profile and atopic skin manifestation were investigated. The descriptive comparison of the cohorts (EAS ≤ 7 and EAS ≥ 10) was performed by using MOAHLFA Index [22, 23]. The MOAHLFA Index includes the parameters male sex, age ≥ 40 years and an occupationally caused dermatitis, and it differentiates between AD and hand, leg and face dermatitis. Differences in population characteristics between the two cohorts (EAS ≤ 7 and EAS ≥ 10) were tested for statistical significance by chi-squared test ($\chi^2$). Statistical significance of differences in sensitization frequencies in disjunct subgroups of patients was determined by non-overlapping 95% confidence intervals (CI) of the age and sex-standardized proportions of positive reactions. Further, we performed logistic regression analyses with positive reactions to the ten most frequent allergens as target variables. Age (< 40 vs. ≥ 40 years), sex, atopy score (EAS ≤ 7 and EAS ≥ 10), past or present AD (yes/no) and medical profession (yes/no) served as explanatory variables. (The latter variable was selected because medical professions were over-represented among patients with a high EAS (18.4% vs. 6.8%) (Table S2, online Supporting Information). Data was managed and analyzed using the statistical analysis software SAS®, version 9.4 (SAS Institute, Cary, NC, USA). A P value of $P < 0.05$ was considered to be significant.

Results

Atopic skin diathesis is highly associated with past or present atopic diseases

The well-established MOAHLFA index [22] was used to characterize the study population regarding the effects of atopic skin diathesis according to the extensive EAS (Table S1, online Supporting Information). Briefly, EAS ≤ 7 was rated as “no or improbable risk” of atopic skin diathesis, whereas EAS ≥ 10 was considered as atopic skin predisposition/diathesis. Values of 8 or 9 did not allow a clear assignment (indeterminate range) and were therefore discarded. All MOAHLFA items differed significantly between patients with and without atopic skin diathesis (Table 1). As expected, atopic skin diathesis was highly associated with past or present atopic diseases (AD, allergic rhinitis, and allergic asthma). Further, patients with atopic skin diathesis were significantly more often diagnosed with occupational (53.5% vs. 34.5%) and hand dermatitis (68.4% vs. 46.1%). Leg and face dermatitis were significantly less common in patients with atopic skin diathesis. Interestingly, there were more female patients and younger patients (< 40 years) among those with atopic skin diathesis. However, these parameters differed to a lesser extent than the other items of the MOAHLFA index. Next, we assessed relevant differences in the final main diagnosis made by the dermatologist, which was established immediately after reading of the patch test (Table 2). As expected, individuals with atopic skin diathesis were more often diagnosed with AD (37.1% vs. 6.2%). These patients were also more often diagnosed with “pruritus of unknown origin” and “dyshidrotic eczema”; which may be related to atopy, at least in some individuals. Interestingly, “chronic irritant contact dermatitis” was diagnosed at identical rates in both groups, independent of atopy (17.6% vs. 17.7%). Allergic contact dermatitis and hyperkeratotic eczema were more frequent in patients without atopic skin diathesis. Since occupational exposure is one of the most important factors...
in sensitization to specific compounds and subsequent development of contact dermatitis, we explored this variable in greater detail by analyzing atopic skin diathesis and the self-reported occupation (Table S2, online Supporting Information). Individuals with atopic skin diathesis worked more often in medical professions (18.4 % vs. 6.8 %). In addition, hairdressers were distinctly more frequent in the group with atopic skin diathesis (4.6 % vs. 2.0 %), albeit with an overall low number of cases.

### Atopy is associated with sensitization to selected allergens

All patients received patch-tests with the DKG baseline series. Focusing on the core analysis of this study, 43.0 % patients (1,938/4,509 patients) displayed at least one positive reaction to the tested allergens. This proportion was significantly higher among patients with atopic skin diathesis, compared to individuals without atopic skin diathesis (49.1 % vs. 38.3 %) (Table 3). As mentioned earlier, reaction frequencies to different allergens are influenced by distribution of age and sex [23]. After detailed characterization of the subgroups with and without atopic skin diathesis, respectively, we calculated frequencies of sensitization to allergens from the baseline series (Table 4). Interestingly, sensitization frequencies of most of the 32 allergens were not associated with atopy. Significantly higher sensitization rates in individuals with atopic skin diathesis were seen only to MI, MCI/MI, fragrance mix I, potassium dichromate, and compositae mix II (Table 4). However, a statistical comparison of patch test results in individuals with and without atopic skin diathesis is presented in Table 5.

### Table 1

Descriptive characterization by MOAHLFA-index, plus allergic rhinitis/asthma, in patients without atopic skin diathesis (EAS ≤ 7) versus with atopic skin diathesis (EAS ≥ 10).

| MOAHLFA index | EAS ≤ 7 (n = 2165) | EAS ≥ 10 (n = 1743) | Significance |
|---------------|-------------------|-------------------|--------------|
|               | n                 | %                 | n            | %             | Chi²-test, P value |
| Male          | 1010              | 46.7              | 694          | 39.8          |                |
| Occupational dermatitis | 746          | 34.5              | 932          | 53.5          |                |
| Atopic dermatitis | 222              | 10.3              | 1142         | 65.5          |                |
| Hand dermatitis | 998               | 46.1              | 1193         | 68.4          |                |
| Leg dermatitis  | 139               | 6.4               | 25           | 1.4           |                |
| Face dermatitis | 287               | 13.3              | 148          | 8.5           |                |
| Age ≥ 40 years | 1601              | 73.9              | 1128         | 64.7          |                |
| Allergic rhinitis | 227               | 10.5              | 747          | 42.9          |                |
| Allergic asthma | 67                | 3.1               | 281          | 16.1          |                |

### Table 2

Final main diagnosis of the dermatologist after evaluation of the patch test, in individuals without atopic skin diathesis (EAS ≤ 7) versus atopic skin diathesis (EAS ≥ 10).

| Final main diagnosis                   | EAS ≤ 7 (n = 2165) | EAS ≥ 10 (n = 1743) | Significance |
|---------------------------------------|-------------------|-------------------|--------------|
|                                       | n                 | %                 | n            | %             | Chi²-test, P value |
| Atopic dermatitis                     | 135               | 6.2               | 647          | 37.1          | <0.0001          |
| Chronic irritant contact dermatitis   | 380               | 17.6              | 308          | 17.7          | 0.92             |
| Allergic contact dermatitis           | 441               | 20.4              | 191          | 11.0          | <0.0001          |
| Hyperkeratotic eczema                 | 175               | 8.1               | 63           | 3.6           | <0.0001          |
| Dyshidrotic eczema                    | 101               | 4.7               | 112          | 6.4           | 0.016            |
| Pruritus of unknown origin            | 79                | 3.6               | 91           | 5.2           | 0.017            |
Contact allergy in atopic skin diathesis

Atopic skin diathesis proved to be the most important intrinsic factor for contact sensitization

To address the question whether atopic skin diathesis is an independent influencing variable for sensitization to specific contact allergens, a logistic regression analysis was performed. The effect of a high EAS on reactivity to the ten most frequent allergens, controlled for past or present AD, age, sex, and having a medical profession, is presented in Table 5. Atopic skin diathesis was found to be associated with a significantly higher risk of sensitization to MI and MCI/MI, thiuram mix, as well as nickel, cobalt and chromium. In contrast, past or present AD was identified as being a less relevant variable, increasing only the risk of sensitization to MI and fragrance mix I. Unexpectedly, past or present AD appeared as a protective factor for a sensitization to Balsam of Peru. Results regarding the influence of sex and age confirmed published knowledge. Male sex meant an increased risk of being sensitized to chromium and colophony, but was negatively associated with sensitizations to nickel, cobalt, or fragrances. A higher age (40+) increased the risk of fragrance allergy and sensitization to MCI/MI and MI. Having a medical profession significantly increased the risk of sensitization to MCI/MI, fragrance mix II, and thiuram mix.

Discussion

The aim of this study was to investigate the overall and specific prevalence of allergic contact sensitizations in patients with and without atopic skin diathesis. Our findings revealed a significantly higher rate of at least one positive patch test in patients with atopic skin diathesis than in those without (49.1 % vs. 38.3 %). Indeed, logistic regression analysis indicated that atopic skin diathesis rather than past or present AD is the most important influencing factor in sensitizations to MCI/MI and MI, thiuram mix, as well as nickel, cobalt and chromium. All other compounds investigated of the DKG baseline series showed identical frequencies in individuals with and without atopic skin diathesis. Some compounds were generally low in number of positive reactions, thus an even larger study group is needed for verification of these results. The EAS, based on atopic signs and symptoms as well as lab results, is a standardized tool to identify atopic skin diathesis in dermatitis patients to estimate their likelihood of having AD [17]. Although the EAS is widely used in Germany to support differentiation of occupational skin
Table 4  Patch testing with 32 allergens from the DKG baseline series. The vehicle was petrolatum unless otherwise marked. Significant differences in age and sex-standardized proportions of patients with positive reactions are marked in bold print. A blue background indicates significantly decreased 95 % confidence intervals (95 % CI) whereas a red background shows significantly increased 95 % CI.

| Substance                                      | Conc. | EAS ≤ 7 (n = 2165) | EAS ≥ 10 (n = 1743) |
|------------------------------------------------|-------|--------------------|--------------------|
|                                                 |       | n[test] | n[pos.] | Age- and sex-standardized %positive [95 % CI] | n[test] | n[pos.] | Age- and sex-standardized %positive [95 % CI] |
|                                                |       |         |         |                                              |         |         |                                              |
| Nickel (II)-sulfate                              | 5 %   | 2144    | 250     | 14.4 [12.6–16.3]                              | 1725    | 300     | 17.9 [16.1–19.8]                              |
| Fragrance mix                                    | 8 %   | 2155    | 152     | 6.0 [5.0–7.1]                                 | 1737    | 165     | 9.2 [7.8–10.6]                                 |
| (Chloro)-Methylisothiazolinone (MCI/MI)          | 0.01 % aq. | 2154    | 60      | 2.7 [1.9–3.5]                                 | 1737    | 133     | 7.2 [5.9–8.4]                                 |
| Cobalt (II)-chloride                             | 1 %   | 2152    | 92      | 4.8 [3.7–5.9]                                 | 1735    | 117     | 6.8 [5.5–8.0]                                 |
| Methylisothiazolinone                            | 0.05 % aq. | 1932    | 59      | 2.9 [2.1–3.8]                                 | 1681    | 114     | 6.4 [5.2–7.6]                                 |
| Fragrance-mix II                                 | 14 %  | 2154    | 90      | 3.7 [2.9–4.6]                                 | 1739    | 94      | 5.0 [4.0–6.0]                                 |
| Potassium dichromate                             | 0.5 % | 2156    | 60      | 2.5 [1.8–3.3]                                 | 1735    | 90      | 4.9 [3.8–5.9]                                 |
| Myroxylon pereirae resin (balsam of Peru)        | 25 %  | 2156    | 150     | 6.0 [4.9–7.0]                                 | 1739    | 83      | 4.3 [3.4–5.2]                                 |
| Colophony                                        | 20 %  | 2153    | 82      | 3.4 [2.6–4.3]                                 | 1737    | 79      | 4.3 [3.3–5.3]                                 |
| Dibromdicyanobutan (Methyldibromo Glut.)        | 0.2 % | 2157    | 50      | 2.0 [1.2–2.6]                                 | 1737    | 57      | 3.0 [2.2–3.8]                                 |
| Compositae mix II                               | 5 %   | 814*    | 8       | 0.8 [0.2–1.4]                                 | 876*    | 25      | 2.6 [1.6–3.7]                                 |
| HICC (e.g. Lyral’)                               | 5 %   | 2158    | 43      | 1.9 [1.3–2.5]                                 | 1739    | 47      | 2.6 [1.8–3.3]                                 |
| Wool alcohols                                    | 30 %  | 2157    | 64      | 2.9 [2.1–3.7]                                 | 1739    | 41      | 2.5 [1.7–3.3]                                 |
| Compositae Mix                                   | 5 %   | 1349*   | 13      | 0.9 [0.3–1.4]                                 | 866*    | 20      | 2.0 [1.1–2.9]                                 |
| Formaldehyde                                     | 1 % aq. | 2159    | 29      | 1.2 [0.7–1.7]                                 | 1739    | 32      | 1.9 [1.2–2.6]                                 |
| Epoxy resin                                      | 1 %   | 2161    | 32      | 1.1 [0.6–1.5]                                 | 1739    | 32      | 1.7 [1.1–2.4]                                 |
| Bufexamac                                        | 5 %   | 2047    | 12      | 0.6 [0.2–1.0]                                 | 1533    | 23      | 1.7 [1.0–2.6]                                 |
| Propolis                                         | 10 %  | 2155    | 58      | 2.6 [1.8–3.3]                                 | 1738    | 31      | 1.6 [1.0–2.2]                                 |
| Ylang ylang oil (I + II)                         | 10 %  | 2098    | 36      | 1.6 [1.0–2.1]                                 | 1701    | 25      | 1.5 [0.9–2.2]                                 |
| Iodopropynyl butylcarbamate                      | 0.2 % | 1933    | 23      | 1.4 [0.7–2.0]                                 | 1687    | 25      | 1.4 [0.8–1.9]                                 |
| N-isopropyl-N’-phenyl-p-phenylenediamine         | 0.1 % | 2157    | 16      | 0.7 [0.3–1.1]                                 | 1738    | 26      | 1.4 [0.8–1.9]                                 |
| Turpentine                                       | 10 %  | 2158    | 33      | 1.3 [0.7–1.8]                                 | 1739    | 22      | 1.1 [0.7–1.6]                                 |
| Jasmine absolute                                 | 5 %   | 2098    | 16      | 0.6 [0.3–0.8]                                 | 1701    | 21      | 1.1 [0.6–1.6]                                 |
Table 4 Continued.

| Substance                                           | Conc. | n [test] | n [pos.] | EAS ≤ 7 (n = 2165) Age- and sex-standardized %positive [95 % CI] | n [test] | n [pos.] | EAS ≥ 10 (n = 1743) Age- and sex-standardized %positive [95 % CI] |
|-----------------------------------------------------|-------|----------|----------|----------------------------------------------------------------|----------|----------|----------------------------------------------------------------|
| Bronopol (2-bromo-2-nitropropane-1,3-diol)          | 0.5 % | 2156     | 15       | 0.5 [0.2–0.7]                                                   | 1738     | 18       | 0.9 [0.5–1.3]                                                   |
| Zinc-diethylthiocarbamate                            | 1 %   | 2158     | 12       | 0.5 [0.2–0.8]                                                   | 1737     | 15       | 0.9 [0.4–1.3]                                                   |
| Mercaptobenzothiazole                                | 2 %   | 2157     | 20       | 1.2 [0.6–1.7]                                                   | 1738     | 15       | 0.9 [0.4–1.4]                                                   |
| Mercapto-Mix without MBT (only CBS, MBTS, MOR)       | 1 %   | 2157     | 19       | 1.1 [0.6–1.7]                                                   | 1739     | 15       | 0.9 [0.4–1.4]                                                   |
| Cetyl stearyl alcohol                                | 20 %  | 2158     | 22       | 1.0 [0.5–1.4]                                                   | 1739     | 8        | 0.5 [0.1–0.8]                                                   |
| P-tert-butylphenol-formaldehyde resin                | 1 %   | 2047     | 18       | 0.8 [0.4–1.2]                                                   | 1539     | 8        | 0.4 [0.1–0.8]                                                   |
| Paraben-Mix                                         | 16 %  | 2158     | 14       | 0.7 [0.3–1.2]                                                   | 1739     | 6        | 0.4 [0.1–0.7]                                                   |

*Reduced number of patients tested because the allergen preparation was not part of the DKG baseline series through the entire study period.

Table 5 Odds ratios with 95 % confidence intervals (95 % CI) resulting from logistic regression analyses with positive reactions (sensitization) to the respective allergen as target variables and five influencing variables. Significant differences are marked in bold print. A blue background marks significantly decreased 95 % CI, and a red background highlights significantly increased 95 % CI.

| Positive reaction to allergen                      | EAS ≥ 10 | Past or present atopic dermatitis | Medical profession | Male sex | Age 40 +                          |
|----------------------------------------------------|----------|-----------------------------------|--------------------|----------|-----------------------------------|
| Methylchloroisothiazolinone/                        | 2.383    | 1.363 [0.956–1.955]               | 1.724 [1.166–2.512]| 0.885 [0.639–1.218] | 1.814 [1.284–2.616] |
| Methylthiazolinone (MCI/MI)                         | 2.089    | 1.036 [0.694–1.555]               | 0.732 [0.392–1.272]| 1.442 [1.025–2.035] | 1.311 [0.906–1.935] |
| Methylenechromate                                   | 1.891    | 1.369 [1.075–2.308]               | 1.281 [0.826–1.941]| 0.902 [0.644–1.260] | 1.725 [1.204–2.523] |
| Cobalt (II)-chloride                                | 1.683    | 0.894 [0.629–1.272]               | 1.031 [0.674–1.535]| 0.580 [0.422–0.790] | 0.948 [0.700–1.297] |
| Thiuram mix                                         | 1.614    | 1.095 [0.710–1.696]               | 1.667 [1.029–2.626]| 0.849 [0.576–1.242] | 1.292 [0.873–1.954] |
| Nickel (II)-sulphate                                | 1.530    | 0.996 [0.785–1.264]               | 1.037 [0.796–1.342]| 0.205 [0.159–0.262] | 0.940 [0.765–1.157] |
| Fragrance-mix II                                    | 1.317    | 0.903 [0.615–1.324]               | 1.993 [1.325–2.943]| 0.756 [0.539–1.053] | 2.053 [1.407–3.083] |
| Colophony                                           | 1.292    | 1.209 [0.801–1.828]               | 0.583 [0.290–1.062]| 1.400 [1.003–1.961] | 1.361 [0.940–2.012] |
| Fragrance mix                                       | 1.193    | 1.381 [1.028–1.857]               | 1.021 [0.712–1.437]| 0.650 [0.453–0.837] | 1.923 [1.447–2.591] |
| Myroxyln pereirae (Balsam of Peru)                  | 0.919    | 0.620 [0.424–0.900]               | 0.920 [0.571–1.425]| 0.672 [0.502–0.895] | 2.453 [1.702–3.646] |
disease from intrinsic skin diseases such as AD, it has never gained similar international recognition and application. Limited diagnostic performance of the EAS has been attributed to insufficient validation of the score in community versus hospital settings and investigator bias due to the presence or absence of flexural dermatitis [24, 25]. Thus, future research for improvement of the EAS or establishment of a superior method to assess atopic skin diathesis should be encouraged. Some studies reported a higher prevalence of ACD in AD [9, 26], while others did not identify relevant differences compared to individuals without AD [7, 10, 13, 27]. Gene expression studies even suggested an attenuated immune response to contact allergens in AD patients, although the authors did not present clinical data for their sampled patient cohort of ten AD patients [6]. Thus, existing data show a trend towards higher allergic sensitization rates in patients with AD, although these differences seem to be modest at best, without dissecting reactivity to specific allergens.

Impaired skin barrier function has been identified as one of the most important pathogenic factors in AD, with filaggrin expression, deficiency of antimicrobial peptides, modified microbiome, and altered composition of intercellular lipids being involved in formation of the deficient skin barrier [28]. A recent systematic review on 40 studies investigating skin penetration and absorption described an almost doubled skin absorption rate of different compounds penetrating the skin of AD patients, compared to healthy controls [29]. However, dinitrochlorobenzene (DNCB) penetration in human skin explants revealed no difference in skin penetration of controls vs. AD patients, independently of filaggrin mutation status [30]. Further, AD patients being sensitized to DNCB responded to a second DNCB challenge with a positive skin reaction in 100 % of patients with mild AD (40/40 patients), whereas only 33 % of patients with severe AD (8/24) displayed a positive challenge test [31].

Current research has tested the hypothesis that hapten-specific properties rather than general effects of immune polarization that favor or counter ACD development may be involved [32]. Thus, manifestation of ACD may depend on (1) hapten-specific properties influencing penetration of the skin barriers, (2) immunological features of the hapten and/or allergen facilitating immune activation in the skin after penetration, (3) status of the immune activation or non-activation condition in the skin/of the host before penetration or incorporation of the allergen. Our patient cohort with atopic skin diathesis showed significantly increased sensitization rates to the metal salts nickel, cobalt, and chromium. Earlier work suggested a functional relationship between nickel allergy and filaggrin mutation status [33]. Of note, no significant difference was found in our study for sensitization rates to the metal salts in correlation to past or present AD, as proposed earlier. Our findings are consistent with a recent meta-analysis that failed to identify a relevant correlation between nickel sensitization and AD [27]. This may be explained by immunological and clinical considerations: (1) Human skin biopsies from positive nickel-patch tests demonstrated an attenuated Th1 and Th2-immune response with increased Th17/IL-23 skewing [6], (2) suitability of patch-testing patients with atopic skin diathesis and/or AD affects test results. Patients with AD are more often suspected to display more doubtful or weak positive reactions (particularly follicular reactions) to metal salts such as nickel sulphate, cobalt chloride, and potassium dichromate [34]. Doubtful irritant reactions are especially seen on Day 1 of patch test reading in patients with a predisposition towards AD (according to the criteria of Hanifin and Rajka), compared to patients without a history or present atopic dermatitis [35]. However, a generalization of this observation should be avoided in light of our recent publication demonstrating a lack of correlation of irritant contact dermatitis (induced by SLS in patch tests) in individuals with atopic skin diathesis or atopic diseases [36].

The frequent use of emollients in AD patients may entail a higher risk for acquisition of ACD towards these compounds. Frequency of contact allergy to MCI/MI was strongly elevated in patients with atopic skin diathesis, but again not in patients with past or current AD. The use of methylisothiazolinone as cosmetic preservative at higher concentrations than before resulted in a dramatic increase of sensitization to MI in the last decade [37]. Patients with atopic skin diathesis were significantly more often affected with occupational dermatitis and hand dermatitis in our study group. Subgroup analyses showed that especially medical professions with atopic skin diathesis have a significantly increased risk for MCI/MI and MI sensitization. These findings are in accordance with the results of a German analysis of ECT results in nurses as well as earlier studies on AD patients in the IVDK network [10, 38].

The higher incidence of sensitization to fragrances in patients with AD is in line with former study results identifying increased fragrance sensitization in AD patients [9, 10]. Interestingly, we confirmed a weak, but significant association of fragrance sensitization with AD, but no association with atopic skin diathesis. Fragrance mix was reported to primarily activate the Th2/Th22-axis [5, 32], which induces similar cytokines as found in acute AD [1]. In our study cohort, fragrance mix I was one of the few allergens increased in patients with AD. However, positive reactions to fragrance mix I are frequently false positives, since patch-testing with the eight individual fragrances from this mix are positive in 35–60 % of patients only. Fragrances are also known as potential substances responsible for irritant reactions in patients with AD [34]. Thus, classifying patients with and without atopic skin diathesis may allow a better discrimination in the assessment of patch test results to fragrances than being positive or negative.
for past or present AD. Our association of sensitization to fragrances with higher age (40+) and medical profession is in line with earlier studies [39, 40].

In summary, we identified some relevant differences in the spectrum of allergic sensitizations in individuals with atopic skin diathesis. Consequently, individuals with atopic skin diathesis may profit from avoidance of a few specific compounds that convey an increased risk of ACD. The overall risk of ACD is largely similar to that of healthy individuals. Owing to this observation, we currently do not suggest the elimination of specific allergens in patients with atopic skin diathesis until more confirmatory studies become available. It seems plausible that epidermal barrier impairment may be a risk factor in acquisition of contact dermatitis; however, it is arguably not the sole explanation for these observations. Since recent findings on ACD have begun to elucidate the different immune-polarizing properties of haptens as well as the relevance of immune-polarizing and genetic or barrier factors of the individual, our data add important new aspects to the growing body of evidence for precision medicine in ACD.

Acknowledgements

Open access funding enabled and organized by Projekt DEAL.

Correspondence to

Susann Forkel, MD
University Medical Center Göttingen
Department of Dermatology, Venereology and Allergology
Robert Koch Strasse 40
37075 Göttingen, Germany
E-mail: susann.forkel@med.uni-goettingen.de;
timo.buhl@med.uni-goettingen.de

References

1. Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387: 1109–22.
2. Grobe W, Bieber T, Novak N. Pathophysiology of atopic dermatitis. J Dtsch Dermatol Ges 2019; 17: 433–40.
3. Owen JL, Vakharia PP, Silverberg JI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. Am J Clin Dermatol 2018; 19: 293–302.
4. Lampel HP, Powell HB. Occupational and hand dermatitis: a practical approach. Clin Rev Allergy Immunol 2019; 56: 60–71.
5. Dhingra N, Shemer A, Correa da Rosa J et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol 2014; 134: 362–72.
6. Correa da Rosa J, Malajian D, Shemer A et al. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. J Allergy Clin Immunol 2015; 135: 712–20.
7. Clemmensen KK, Thomsen SF, Jemec GB, Agner T. Pattern of contact sensitization in patients with and without atopic dermatitis in a hospital-based clinical database. Contact Dermatitis 2014; 71: 75–81.
8. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. working party’s diagnostic criteria for atopic dermatitis. III. independent hospital validation. Br J Dermatol 1994; 131: 406–16.
9. Thyssen JP, Linneberg A, Engkilde K et al. Contact sensitization to common haptens is associated with atopic dermatitis: new insight. Br J Dermatol 2012; 166: 1255–61.
10. Heine G, Schnuch A, Uter W, Worm M. Information Network of Departments of D, German Contact Dermatitis Research G. Type-IV sensitization profile of individuals with atopic eczema: results from the Information Network of Departments of Dermatology (IVDK) and the German Contact Dermatitis Research Group (DKG). Allergy. 2006; 61: 611–6.
11. Hanifin JM, Rajka G. Diagnostic features of atopic eczema. Acta Derm Venereol 1980; 92: 44–7.
12. de Groot AC. The frequency of contact allergy in atopic patients with dermatitis. Contact Dermatitis 1990; 22: 273–7.
13. Landeck L, Schalock P, Baden L, Gonzalez E. Contact sensitization pattern in 172 atopic subjects. Int J Dermatol 2011; 50: 806–10.
14. Weidinger S, Beck LA, Bieber T et al. Atopic dermatitis. Nat Rev Dis Primers 2018; 4: 1.
15. Chylla R, Schnopp C, Volz T. Basic skin care in atopic dermatitis – new and established treatment options. J Dtsch Dermatol Ges 2018; 16: 976–79.
16. Diepgen TL, Fartasch M, Hornstein OP. [Kriterien zur Beurteilung der atopischen Hautdiathese]. Dermal Beruf Umwelt 1991; 39: 79–83.
17. Diepgen TL, Sauerbrei W, Fartasch M. Development and validation of diagnostic scores for atopic dermatitis incorporating criteria of data quality and practical usefulness. J Clin Epidemiol 1996; 49: 1031–8.
18. Vakharia PP, Chopra R, Silverberg Jl. Systematic review of diagnostic criteria used in atopic dermatitis randomized controlled trials. Am J Clin Dermatol 2018; 19: 15–22.
19. Schnuch A, Geier J, Lessmann H et al. Surveillance of contact allergies: methods and results of the Information Network of Departments of Dermatology (IVDK). Allergy 2012; 67: 847–57.
20. Schnuch A, Aberer W, Agathos M et al. [Performing patch testing with contact allergens]. J Dtsch Dermatol Ges 2008; 6: 770–5.
21. Mahler V, Nast A, Bauer A et al. S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1. J Dtsch Dermatol Ges 2019; 17: 1076–93.
22. Schnuch A. PAFS: population-adjusted frequency of sensitization. (I) Influence of sex and age. Contact Dermatitis 1996; 34: 377–82.
23. Schnuch A, Geier J, Uter W et al. National rates and regional differences in sensitization to allergens of the standard series. Population-adjusted frequencies of sensitization (PAFS) in 40,000 patients from a multicenter study (IVDK). Contact Dermatitis 1997; 37: 200–9.
Contact allergy in atopic skin diathesis

development of hand eczema in trainee metal workers. Br J Dermatol 1999; 140: 922–4.
25 Uter W, Schwanz HJ, Pfahlberg A, Gefeller O. Atopic signs and symptoms: assessing the 'atopy score' concept. Dermatology 2001; 202: 4–8.
26 Malajan D, Belsito DV. Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis. J Am Acad Dermatol 2013; 69: 232–7.
27 Hamann CR, Hamann D, Egeberg A et al. Association between atopic dermatitis and contact sensitization: A systematic review and meta-analysis. J Am Acad Dermatol 2017; 77: 70–8.
28 Kim BE, Leung DYM. Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res 2018; 10: 207–15.
29 Halling-Overgaard AS, Kezic S, Jakasa I et al. Skin absorption through atopic dermatitis skin: a systematic review. Br J Dermatol 2017; 177: 84–106.
30 Newell L, Polak ME, Perera J et al. Sensitization via healthy skin programs Th2 responses in individuals with atopic dermatitis. J Invest Dermatol 2013; 133: 2372–80.
31 Uehara M, Sawai T. A longitudinal study of contact sensitivity in patients with atopic dermatitis. Arch Dermatol 1989; 125: 366–8.
32 Classen A, Buhl T, Schubert S et al. The frequency of specific contact allergies is reduced in patients with psoriasis. Br J Dermatol 2019; 180: 315–20.
33 Novak N, Baurecht H, Schäfer T et al. Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. J Invest Dermatol 2008; 128: 1430–5.
34 Chen JK, Jacob SE, Nedorost ST et al. A pragmatic approach to patch testing atopic dermatitis patients: clinical recommendations based on expert consensus opinion. Dermatitis 2016; 27: 186–92.
35 Brasch J, Schnuch A, Uter W. Patch-test reaction patterns in patients with a predisposition to atopic dermatitis. Contact Dermatitis 2003; 49: 197–201.
36 Heetfeld AB, Schill T, Schröder SS et al. Challenging a paradigm: skin sensitivity to sodium lauryl sulfate is independent of atopic diathesis. Br J Dermatol 2020; 183(i): 139–45.
37 Uter W, Gefeller O, Geier J, Schnuch A. Methylchloroisothiazoline/methylisothiazolinone contact sensitization: diverging trends in subgroups of IVDK patients in a period of 19 years. Contact Dermatitis 2012; 67: 125–9.
38 Molin S, Bauer A, Schnuch A, Geier J. Occupational contact allergy in nurses: results from the Information Network of Departments of Dermatology 2003–2012. Contact Dermatitis 2015; 72: 164–71.
39 Schubert S, Bauer A, Molin S et al. Occupational contact sensitization in female geriatric nurses: Data of the Information Network of Departments of Dermatology (IVDK) 2005–2014. J Eur Acad Dermatol Venereol 2017; 31: 469–76.
40 Uter W, Schnuch A, Geier J et al. Association between occupation and contact allergy to the fragrance mix: a multifactorial analysis of national surveillance data. Occup Environ Med 2001; 58: 392–8.